$OMER
OMEROS CORP Stock $omer

$omer Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-K Financial Statement

#000128581917000004 Filed on March 16, 2017

Income Statement

Concept	2017 Q1	2016 Q4	2015 Q4
Revenue	$12.26M	$12.91M	$6.675M
YoY Change	65.21%	93.33%	3608.33%
Cost Of Revenue	$271.0K	$380.0K	$420.0K
YoY Change	-17.13%	-9.52%
Gross Profit	$11.99M	$12.53M	$6.260M
YoY Change	69.01%	100.16%
Gross Profit Margin	97.79%	97.09%	93.78%
Selling, General & Admin	$12.47M	$11.84M	$9.400M
YoY Change	12.24%	25.96%	11.77%
% of Gross Profit	104.04%	94.49%	150.16%
Research & Development	$12.24M	$12.54M	$14.90M
YoY Change	-20.69%	-15.84%	26.81%
% of Gross Profit	102.12%	100.08%	238.02%
Depreciation & Amortization	$120.0K	$90.00K	$50.00K
YoY Change	140.0%	80.0%	-28.57%
% of Gross Profit	1.0%	0.72%	0.8%
Operating Expenses	$24.98M	$24.76M	$24.72M
YoY Change	-7.03%	0.19%	22.62%
Operating Profit	-$12.73M	-$11.86M	-$18.04M
YoY Change	-34.58%	-34.27%	-9.69%
Interest Expense	$2.663M	-$2.450M	-$810.0K
YoY Change	93.67%	202.47%	-10.99%
% of Operating Profit
Other Income/Expense, Net	$299.0K	$270.0K	$340.0K
YoY Change	3.82%	-20.59%	88.89%
Pretax Income	-$15.09M	-$19.63M	-$19.83M
YoY Change	-26.53%	-1.01%	-4.25%
Income Tax
% Of Pretax Income
Net Earnings	-$15.09M	-$19.63M	-$19.83M
YoY Change	-26.53%	-0.98%	-4.28%
Net Earnings / Revenue	-123.11%	-152.13%	-297.02%
Basic Earnings Per Share
Diluted Earnings Per Share	-$344.3K	-$454.1K	-$522.0K
COMMON SHARES
Basic Shares Outstanding	43.82M shares	42.92M shares	37.97M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q4	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.70M	$45.30M	$28.30M
YoY Change	155.3%	60.07%	310.14%
Cash & Equivalents	$1.282M	$2.224M	$1.365M
Short-Term Investments	$32.40M	$43.10M	$26.90M
Other Short-Term Assets	$3.300M	$1.800M	$1.900M
YoY Change	32.0%	-5.26%	1483.33%
Inventory	$960.0K	$1.128M	$472.0K
Prepaid Expenses	$3.260M	$1.766M	$1.894M
Receivables	$13.50M	$12.00M	$6.300M
Other Receivables	$0.00	$100.0K	$173.0K
Total Short-Term Assets	$51.35M	$60.26M	$37.15M
YoY Change	111.14%	62.23%	310.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.215M	$1.181M	$951.0K
YoY Change	35.3%	24.19%	21.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.800M	$0.00	$219.0K
YoY Change	7845.21%	-100.0%	-34.04%
Total Long-Term Assets	$7.050M	$7.016M	$11.85M
YoY Change	-39.48%	-40.79%	560.85%
TOTAL ASSETS
Total Short-Term Assets	$51.35M	$60.26M	$37.15M
Total Long-Term Assets	$7.050M	$7.016M	$11.85M
Total Assets	$58.40M	$67.28M	$49.00M
YoY Change	62.36%	37.32%	352.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.409M	$2.519M	$6.428M
YoY Change	-54.82%	-60.81%	30.78%
Accrued Expenses	$14.34M	$13.35M	$9.752M
YoY Change	18.28%	36.94%	37.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$228.0K	$198.0K	$73.00K
YoY Change	230.43%	171.23%	-98.85%
Total Short-Term Liabilities	$16.97M	$16.07M	$16.25M
YoY Change	-3.13%	-1.12%	-11.26%
LONG-TERM LIABILITIES
Long-Term Debt	$80.50M	$79.51M	$49.77M
YoY Change	61.09%	59.76%	90.52%
Other Long-Term Liabilities	$9.000M	$9.100M	$9.200M
YoY Change	-2.17%	-1.09%	1.1%
Total Long-Term Liabilities	$80.50M	$79.51M	$49.77M
YoY Change	61.09%	59.76%	90.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.97M	$16.07M	$16.25M
Total Long-Term Liabilities	$80.50M	$79.51M	$49.77M
Total Liabilities	$97.48M	$95.58M	$66.02M
YoY Change	44.42%	44.77%	48.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$485.0M	-$469.9M	-$403.1M
YoY Change	14.47%	16.56%	22.89%
Common Stock	$439.0K	$438.0K	$380.0K
YoY Change	12.28%	15.26%	11.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$48.11M	-$37.45M	-$26.23M
YoY Change
Total Liabilities & Shareholders Equity	$58.40M	$67.28M	$49.00M
YoY Change	62.36%	37.32%	352.23%

Cashflow Statement

Concept	2017 Q1	2016 Q4	2015 Q4
OPERATING ACTIVITIES
Net Income	-$15.09M	-$19.63M	-$19.83M
YoY Change	-26.53%	-0.98%	-4.28%
Depreciation, Depletion And Amortization	$120.0K	$90.00K	$50.00K
YoY Change	140.0%	80.0%	-28.57%
Cash From Operating Activities	-$12.70M	-$10.86M	-$16.60M
YoY Change	-23.61%	-34.58%	5.8%
INVESTING ACTIVITIES
Capital Expenditures	$72.00K	-$50.00K	-$50.00K
YoY Change		0.0%	150.0%
Acquisitions
YoY Change
Other Investing Activities	$10.74M	-$5.960M	$7.500M
YoY Change	-26.59%	-179.47%	-48.28%
Cash From Investing Activities	$10.66M	-$6.020M	$7.440M
YoY Change	-27.12%	-180.91%	-48.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.147M
YoY Change	15193.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.096M	8.800M	9.920M
YoY Change	-31.88%	-11.29%	1109.76%
NET CHANGE
Cash From Operating Activities	-$12.70M	-10.86M	-16.60M
Cash From Investing Activities	$10.66M	-6.020M	7.440M
Cash From Financing Activities	$1.096M	8.800M	9.920M
Net Change In Cash	-$942.0K	-8.080M	760.0K
YoY Change	143.41%	-1163.16%	-300.0%
FREE CASH FLOW
Cash From Operating Activities	-$12.70M	-$10.86M	-$16.60M
Capital Expenditures	$72.00K	-$50.00K	-$50.00K
Free Cash Flow	-$12.77M	-$10.81M	-$16.55M
YoY Change	-23.18%	-34.68%	5.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	dei	Document Type DocumentType	10-K
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0001285819
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43822133	shares
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q2	dei	Entity Public Float EntityPublicFloat	386370281	USD
CY2016	dei	Entity Registrant Name EntityRegistrantName	OMEROS CORP
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	dei	Trading Symbol TradingSymbol	OMER
CY2015Q4	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	1108000	USD
CY2016Q4	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	1167000	USD
CY2015Q4	omer	Accrued Contract Research Costs AccruedContractResearchCosts	2973000	USD
CY2016Q4	omer	Accrued Contract Research Costs AccruedContractResearchCosts	3030000	USD
CY2016	omer	Beginning Year Of Expiry For Net Operating Loss Carryforwards BeginningYearOfExpiryForNetOperatingLossCarryforwards	2018
CY2016Q4	omer	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1
CY2016	omer	Defined Contribution Plan Maximum Employer Matching Contribution Amount DefinedContributionPlanMaximumEmployerMatchingContributionAmount	4000	USD
CY2014	omer	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.02
CY2015	omer	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.01
CY2015	omer	Sales Agreement Net Proceeds SalesAgreementNetProceeds	1436000	USD
CY2016	omer	Sales Agreement Net Proceeds SalesAgreementNetProceeds	7000	USD
CY2016Q4	omer	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber	3240515	shares
CY2016	omer	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.03
CY2016	omer	Ending Year Of Expiry For Net Operating Loss Carryforwards EndingYearOfExpiryForNetOperatingLossCarryforwards	2036
CY2016Q4	omer	Long Term Purchase Commitment Termination Fee LongTermPurchaseCommitmentTerminationFee	2200000	USD
CY2016Q4	omer	Net Operating Leases Future Minimum Payments Due NetOperatingLeasesFutureMinimumPaymentsDue	49347000	USD
CY2016Q4	omer	Net Operating Leases Future Minimum Payments Due Current NetOperatingLeasesFutureMinimumPaymentsDueCurrent	3811000	USD
CY2016Q4	omer	Net Operating Leases Future Minimum Payments Due In Five Years NetOperatingLeasesFutureMinimumPaymentsDueInFiveYears	4552000	USD
CY2016Q4	omer	Net Operating Leases Future Minimum Payments Due In Four Years NetOperatingLeasesFutureMinimumPaymentsDueInFourYears	4355000	USD
CY2016Q4	omer	Net Operating Leases Future Minimum Payments Due In Three Years NetOperatingLeasesFutureMinimumPaymentsDueInThreeYears	4035000	USD
CY2016Q4	omer	Net Operating Leases Future Minimum Payments Due In Two Years NetOperatingLeasesFutureMinimumPaymentsDueInTwoYears	3882000	USD
CY2016Q4	omer	Net Operating Leases Future Minimum Payments Due Thereafter NetOperatingLeasesFutureMinimumPaymentsDueThereafter	28712000	USD
CY2014	omer	Noncash Transaction Conversion Of Accrued Interest Into Notes Payable NoncashTransactionConversionOfAccruedInterestIntoNotesPayable	0	USD
CY2015	omer	Noncash Transaction Conversion Of Accrued Interest Into Notes Payable NoncashTransactionConversionOfAccruedInterestIntoNotesPayable	0	USD
CY2016	omer	Noncash Transaction Conversion Of Accrued Interest Into Notes Payable NoncashTransactionConversionOfAccruedInterestIntoNotesPayable	516000	USD
CY2016Q4	omer	Numberof Suppliers NumberofSuppliers	1	supplier
CY2014	omer	Sales Agreement Net Proceeds SalesAgreementNetProceeds	68000	USD
CY2016	omer	Warrant Expiration Date WarrantExpirationDate	2023-05-18
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6428000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2519000	USD
CY2015Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	6208000	USD
CY2016Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	11937000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9752000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13354000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2400000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2223000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2432000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2732000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	376528000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	432002000	USD
CY2014	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	863000	USD
CY2015	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	0	USD
CY2016	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	0	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	8918000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9581000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	13582000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	863000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	758000	USD
CY2015	us-gaap	Advertising Expense AdvertisingExpense	885000	USD
CY2016	us-gaap	Advertising Expense AdvertisingExpense	672000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8918000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9581000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13582000	USD
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8915904	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9059485	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9909976	shares
CY2015Q4	us-gaap	Assets Assets	48995000	USD
CY2016Q4	us-gaap	Assets Assets	67278000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	37146000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	60262000	USD
CY2015Q4	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	26898000	USD
CY2016Q4	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	43107000	USD
CY2015Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	279000	USD
CY2016Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	522000	USD
CY2014	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	200000	USD
CY2015	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	137000	USD
CY2016	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	404000	USD
CY2015Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	367000	USD
CY2016Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	774000	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	281000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	522000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Rolling After Year Five CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive	0	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Five CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive	5000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Four CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour	31000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Three CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree	89000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Two CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo	199000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Next Rolling Twelve Months CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths	198000	USD
CY2015Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	98000	USD
CY2016Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	230000	USD
CY2015Q4	us-gaap	Cash Cash	1400000	USD
CY2016Q4	us-gaap	Cash Cash	2200000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1384000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	354000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1365000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2224000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1030000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1011000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	859000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	45300000	USD
CY2016Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.94
CY2009Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	12.25
CY2016Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	100602	shares
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	749250	shares
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10434121	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38040891	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43819133	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38040891	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43819133	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	380000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	438000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-73673000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-75096000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66745000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1041000	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1412000	USD
CY2015Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	54029000	USD
CY2016Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	85063000	USD
CY2016Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	5000000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4000000	USD
CY2015Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	3750000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	3958000	USD
CY2015Q4	us-gaap	Deferred Discounts Finance Charges And Interest Included In Receivables DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables	191000	USD
CY2016Q4	us-gaap	Deferred Discounts Finance Charges And Interest Included In Receivables DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables	297000	USD
CY2015Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	437000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1395000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9207000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9142000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	139054000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	163972000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	110092000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	126410000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	30600000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	50000000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2744000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4401000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	14800000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	14758000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	18741000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8136000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11102000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	3324000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	3318000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	139054000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	163972000	USD
CY2016	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.04
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	317000	USD
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	209000	USD
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000	USD
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.22
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.53
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.00
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.45
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.65
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.35
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.41
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.37
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.01
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.00
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.00
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.02
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.02
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.04
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.05
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.04
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2590000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4551000	USD
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	19000000	USD
CY2016	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M24D
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-863000	USD
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1315000	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5595000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22601000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35327000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43782000	USD
CY2015Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	136000	USD
CY2016Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	0	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5459000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4195000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-319000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	568000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-96000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	656000	USD
CY2014	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	902000	USD
CY2015	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	157000	USD
CY2016	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-65000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	987000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	586000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-347000	USD
CY2014	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	13000	USD
CY2015	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	6125000	USD
CY2016	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	5520000	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	10000000	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-4844000	USD
CY2014	us-gaap	Interest Expense InterestExpense	3470000	USD
CY2015	us-gaap	Interest Expense InterestExpense	3573000	USD
CY2016	us-gaap	Interest Expense InterestExpense	7819000	USD
CY2014	us-gaap	Interest Paid InterestPaid	2674000	USD
CY2015	us-gaap	Interest Paid InterestPaid	4236000	USD
CY2016	us-gaap	Interest Paid InterestPaid	5293000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	221000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	173000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	472000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	1128000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	93000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	101000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	158000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	854000	USD
CY2014	us-gaap	Investment Income Net InvestmentIncomeNet	-195000	USD
CY2015	us-gaap	Investment Income Net InvestmentIncomeNet	1030000	USD
CY2016	us-gaap	Investment Income Net InvestmentIncomeNet	945000	USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	289000000	USD
CY2015	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	492000	USD
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	313000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48995000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67278000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16253000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16071000	USD
CY2015Q4	us-gaap	Loans Payable LoansPayable	3750000	USD
CY2016Q4	us-gaap	Loans Payable LoansPayable	4000000	USD
CY2016Q4	us-gaap	Loans Payable LoansPayable	4025000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	80516000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	70000000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	81038000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal After Year Five LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive	34507000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Five LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive	46014000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Four LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour	31000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Three LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree	89000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Two LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo	199000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Repayments Of Principal In Next Twelve Months LongTermDebtAndCapitalLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths	198000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	73000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	198000	USD
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths	0	USD
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive	34507000	USD
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive	46009000	USD
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour	0	USD
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree	0	USD
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo	0	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	49769000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	79512000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50857000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	86826000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	68698000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6157000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20606000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16335000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-58044000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-65209000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-51504000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-73673000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-18669000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-16680000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-19921000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-19826000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-75096000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-20539000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-12612000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-13962000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-19632000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-66745000	USD
CY2015Q4	us-gaap	Notes Payable NotesPayable	50000000	USD
CY2016Q4	us-gaap	Notes Payable NotesPayable	80516000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	26871000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	20933000	USD
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2014	us-gaap	Operating Expenses OperatingExpenses	70547000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	18318000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	19154000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	22560000	USD
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	24715000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	84747000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	23327000	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	24762000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	95893000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-70008000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17930000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15967000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19301000	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-18040000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-71238000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19452000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10929000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12038000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-11857000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-54276000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	51605000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	4474000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals	2258000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	4552000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4690000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4632000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4545000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	28712000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Receivable Current OperatingLeasesFutureMinimumPaymentsReceivableCurrent	663000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Five Years OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears	0	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Four Years OperatingLeasesFutureMinimumPaymentsReceivableInFourYears	335000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Three Years OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears	597000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Two Years OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears	663000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Receivable Thereafter OperatingLeasesFutureMinimumPaymentsReceivableThereafter	0	USD
CY2015Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	325900000	USD
CY2016Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	378900000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	681000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2383000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	219000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2015Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	173000	USD
CY2016Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	100000	USD
CY2014	us-gaap	Paid In Kind Interest PaidInKindInterest	738000	USD
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest	1045000	USD
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	1461000	USD
CY2015Q4	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	248000	USD
CY2016Q4	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	700000	USD
CY2014	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	521000	USD
CY2015	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2673000	USD
CY2016	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	5700000	USD
CY2014	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	244000	USD
CY2015	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	436000	USD
CY2016	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1501000	USD
CY2014Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2500000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4900000	USD
CY2014	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	58849000	USD
CY2015	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	91766000	USD
CY2016	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	73966000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	240000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	126000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1894000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1766000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37800000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	79100000	USD
CY2016Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37300000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37754000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	79076000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	38039000	USD
CY2014	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	32000000	USD
CY2015	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	50000000	USD
CY2016	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	100000000	USD
CY2014	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	65034000	USD
CY2015	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	71400000	USD
CY2016	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	57757000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1868000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2859000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3153000	USD
CY2016Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	8000	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1400000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3383000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3913000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	951000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1181000	USD
CY2015Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	6517000	USD
CY2016Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	12037000	USD
CY2014	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	20000000	USD
CY2015	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	32000000	USD
CY2016	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	70137000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47946000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48379000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50699000	USD
CY2015Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	10679000	USD
CY2016Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	5835000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-403142000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-469887000	USD
CY2014	us-gaap	Revenue From Grants RevenueFromGrants	539000	USD
CY2015	us-gaap	Revenue From Grants RevenueFromGrants	245000	USD
CY2016	us-gaap	Revenue From Grants RevenueFromGrants	173000	USD
CY2014	us-gaap	Revenues Revenues	539000	USD
CY2015Q1	us-gaap	Revenues Revenues	388000	USD
CY2015Q2	us-gaap	Revenues Revenues	3187000	USD
CY2015Q3	us-gaap	Revenues Revenues	3259000	USD
CY2015Q4	us-gaap	Revenues Revenues	6675000	USD
CY2015	us-gaap	Revenues Revenues	13509000	USD
CY2016Q1	us-gaap	Revenues Revenues	7419000	USD
CY2016Q2	us-gaap	Revenues Revenues	10004000	USD
CY2016Q3	us-gaap	Revenues Revenues	11289000	USD
CY2016Q4	us-gaap	Revenues Revenues	12905000	USD
CY2016	us-gaap	Revenues Revenues	41617000	USD
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	13264000	USD
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	41444000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	8918000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	9581000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	13582000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.73
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.71
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.74
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13600000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	143261	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	12.92
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	3128567	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.39
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.31
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.89
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11162000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0187
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0168
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0163
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6568859	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.87
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2900000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3900000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8310235	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9809374	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.97
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.66
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	11155000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9483392	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.60
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.12
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.72
CY2014	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	86000	shares
CY2015	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	4200	shares
CY2016	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	38000	shares
CY2014Q1	us-gaap	Share Price SharePrice	11.50
CY2015Q1	us-gaap	Share Price SharePrice	20.03
CY2016Q3	us-gaap	Share Price SharePrice	11.50
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M3D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M15D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M12D
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	11087000	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M30D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M13D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y0M19D
CY2014	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	0	USD
CY2015	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	0	USD
CY2016	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	758000	USD
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3500000	shares
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3400000	shares
CY2016Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3500000	shares
CY2014	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	28653	shares
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1486167	shares
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37754000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	79076000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37314000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1800000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1423000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3146000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-18384000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-42654000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-26234000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-37447000	USD
CY2015	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2016	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	212000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	212000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	212000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	25800000	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	30400000	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	24900000	USD
CY2016Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	758000	USD
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33234294	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37560257	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40446410	shares
CY2016	us-gaap	Advertising Cost Policy Expensed Advertising Cost AdvertisingCostPolicyExpensedAdvertisingCost	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Advertising</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Advertising costs, which we consider to be media and marketing materials, are expensed as incurred. We incurred </font><font style="font-family:inherit;font-size:10pt;">$672,000</font><font style="font-family:inherit;font-size:10pt;"> and $</font><font style="font-family:inherit;font-size:10pt;">885,000</font><font style="font-family:inherit;font-size:10pt;"> in advertising expense during the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. We had no similar expenses during the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:24px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Major Suppliers</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use a single contract manufacturer to supply OMIDRIA and generally a single contract manufacturer to produce clinical trial material which creates a concentration of risk for us.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a non-exclusive agreement with Hospira Worldwide, Inc. (Hospira), a wholly owned subsidiary of Pfizer, Inc., for the commercial supply of OMIDRIA, and Hospira has produced product validation batches of OMIDRIA which are currently undergoing testing prior to seeking FDA approval of the Hospira manufacturing facility. We are not permitted to sell any OMIDRIA produced by Hospira, however, until the Hospira manufacturing facility is approved by the FDA.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> source of supply is utilized for OMIDRIA and generally one source for each of our product candidates, other sources are available should we need to change suppliers. We endeavor to maintain reasonable levels of drug supply for our commercial and clinical trial use. A change in suppliers, however, could cause a delay in delivery of OMIDRIA or our clinical trial material that would adversely affect our business. </font></div></div>
CY2016	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Organization</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. </font></div></div>
CY2016	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior periods in the consolidated balance sheets, the statements of cash flows and the accompanying notes to conform with the current presentation. None of these reclassifications impacted our net loss or working capital as they pertained to the presentation of debt matters including issuance costs, extinguishment losses, early payments and proceeds.</font></div></div>
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, stock-based compensation expense and accruals for clinical trials, manufacturing of drug product and clinical drug supply and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001285819-17-000004-index-headers.html	Edgar Link	pending
0001285819-17-000004-index.html	Edgar Link	pending
0001285819-17-000004.txt	Edgar Link	pending
0001285819-17-000004-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
omer-201412_chartx20416a02.jpg	Edgar Link	pending
omer-20161231.xml	Edgar Link	completed
omer-20161231.xsd	Edgar Link	pending
omer-20161231x10k.htm	Edgar Link	pending
omer-20161231_cal.xml	Edgar Link	unprocessable
omer-20161231_def.xml	Edgar Link	unprocessable
omer-20161231_lab.xml	Edgar Link	unprocessable
omer-20161231_pre.xml	Edgar Link	unprocessable
omer-ex1028_20161231.htm	Edgar Link	pending
omer-ex1038_20161231.htm	Edgar Link	pending
omer-ex106_20161231.htm	Edgar Link	pending
omer-ex121_ratioofearnings.htm	Edgar Link	pending
omer-ex231_consentofindepe.htm	Edgar Link	pending
omer-ex311_20161231.htm	Edgar Link	pending
omer-ex312_20161231.htm	Edgar Link	pending
omer-ex321_20161231.htm	Edgar Link	pending
omer-ex322_20161231.htm	Edgar Link	pending
omer-ex991_20161231.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OMER
OMEROS CORP Stock $omer

2017 Q1 Form 10-K Financial Statement

#000128581917000004 Filed on March 16, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER OMEROS CORP Stock $omer

2017 Q1 Form 10-K Financial Statement

#000128581917000004 Filed on March 16, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER
OMEROS CORP Stock $omer